There is a paucity in the literature of papers addressing molecular mechanisms of new peptide polyagonists and extending these to preclinical and clinical data
Acknowledgements Eva Kosek declares the following competing interests: lecturing/consulting for Orion Pharma, Eli Lilly, and UCB
Figure 8 Following advancements in penetration depth and targeting efficiency, the research frontier is now shifting toward exploring different modes of cell death, aiming to go beyond classical ICD and induce more intense, highly immunogenic forms of death to fully activate the immune system
Caloric restriction delays aging-induced cellular phenotypes in rhesus monkey skeletal muscle
There is a naivete on the part of a lot of patients, particularly younger ones, Avorn says in an interview with Vanity Fair
Several GLP-1 agonists are part of this program, including: Exenatide: Results from a large, phase 2 trial in 2017 suggested that exenatide may slow Parkinsons progression
